Kornimate/medical-research-clean huggingface dataset:
the potential role of compounds derived from ultra-processed foods in the pathogenesis of atopic dermatitis in pediatric age

Conditions: Atopic Dermatitis

Summary: atopic dermatitis (ad) is a common chronic inflammatory skin condition, primarily affecting children in urban and high-income areas. its prevalence has increased significantly over the past 30 years, with up to 20% of children affected, often within their first year of life. ad is characterized by erythematous, scaly, pruritic lesions, xerosis, and frequent atopy, with distinct clinical features in children compared to adults. the pathophysiology of ad involves skin barrier dysfunction, immune response alterations, and environmental triggers. genetic factors, particularly mutations in the filaggrin gene, play a significant role in severe ad, leading to increased water loss and skin dehydration. immunologically, a th2-predominant response drives inflammation, and environmental exposures, such as air pollutants and irritants, exacerbate the condition. recent studies suggest that dietary habits, particularly a high intake of ultra-processed foods (upfs), may contribute to ad by activating inflammatory pathways. upfs, rich in advanced glycation end products (ages), induce oxidative stress and inflammation, potentially worsening skin damage. this study aims to explore the potential role of upf-derived compounds, especially ages, in the pathogenesis of pediatric ad.


Eligibility criteria:
inclusion criteria: * caucasian subjects, both sexes, age: ≥6 months and ≤10 years, with a confirmed diagnosis of atopic dermatitis, and healthy controls matched for age and sex without atopic dermatitis; * written informed consent obtained from the participants and/or their parents/legal guardians. exclusion criteria: * non-caucasian ethnicity; age \ 10 years * presence of other chronic conditions: hypereosinophilic syndrome, fungal or viral infections, connective tissue disorders, autoimmune diseases, vasculitis, bullous dermatoses (e.g., pemphigus), drug hypersensitivity reactions, graft-versus-host disease, monogenic disorders (e.g., marfan syndrome type 2, hyper-ige syndrome) * presence of scars, nevi, or unusual skin lesions on both forearms * absence of written informed consent
diabetes mellitus care decision making model through data mining

Conditions: Diabetes Mellitus

Summary: we tried to use data mining method to find out the new model of factors that affects the progression of diabetes mellitus.

the advanced development of medical technology had led to the accumulation of a large amount of medical data. unfortunately, these useful and meaningful clinical data were not properly managed or analyzed. therefore, data mining technology has become an essential instrument for hospital management and medical research. possible meaningful information can be obtained from the database through data mining. about 2,000 diabetic patients had been enrolled in diabetes care program since oct 2002 in our hospital. we intend to look for the determining factors that affect the prognosis of diabetes mellitus in our patients group.

Eligibility criteria:
inclusion criteria: * diabetes mellitus who had been enrolled into the diabetes care program from year 2002 until 2007. exclusion criteria: * none

Keywords: diabetes mellitus care decision data mining
goldmann applanation tonometry, dynamic contour tonometry, and corvis st tonometer

Conditions: Glaucoma

Summary: the study is investigating intra ocular pressure (iop) by goldmann applanation tonometry, dynamic contour tonometry, and the corvis st tonometer.

the aim of the study is to approach the "true" intra ocular pressure (iop) by correlating the difference between iop by goldmann applanation tonometry to the iop by dynamic contour tonometry to the biomechanical parameters of the cornea measured by corvis st. therefore the investigators gain new findings about the influence of the biomechanical corneal parameters on the iop. in order to do so the investigators want to examine 50 glaucoma eyes and 50 non-glaucoma eyes with goldmann applanation tonometry, dynamic contour tonometry, and corvis st.

Eligibility criteria:
inclusion criteria for the glaucoma group: * diagnosis of glaucoma * 18 years old or older with no upper limit exclusion criteria for the glaucoma group: * iop lowering surgery within the last 3 weeks * any corneal surgery in the past * bad fixation * insufficient measurement quality with any of the study devices inclusion criteria for the healthy control group: * no diagnosis of glaucoma * 18 years old or older with no upper limit exclusion criteria for the healthy control group: * any diagnosis of glaucoma * iop lowering surgery within the last 3 weeks * any corneal surgery in the past * bad fixation * insufficient measurement quality with any of the study devices

Keywords: glaucoma intraocular pressure
dpp-4 inhibitor and serum bnp level of diabetic patients with congestive heart failure

Conditions: Heart Failure; Diabetes Mellitus

Summary: we thought to investigate the influence of dpp-4 inhibitor on the serum bnp level of diabetic patients with congestive heart failure. this study consists of two protocols. in the first protocol, diabetic patients with high level of serum bnp (100-2000 pg/ml) receiving outpatient treatment with any type of dpp-4 inhibitor at our institution will be enrolled. after baseline data collection, dpp-4 inhibitor will be suspended for one month and serum bnp will be measured. the dpp-4 inhibitor will be resumed and after another month, serum bnp will be measured again. in the other protocol, diabetic patients who were hospitalized due to heart failure were enrolled. dpp-4 inhibitor will be started (if the patient is not taking a dpp-4 inhibitor) or suspended (if the patient is taking a dpp-4 inhibitor) after stabilization of heart failure, and serum bnp will be measured before and after the drug administration or suspension.


Eligibility criteria:
outpatient arm inclusion criteria: * type 2 diabetes patient with congestive heart failure under treatment with dpp-4 inhibitor (sitagliptin, vildagliptin, alogliptin, linagliptin, teneligliptin, anagliptin or saxagliptin) . * high serum bnp (100-2000pg/ml). * patients who have given informed consent to participation in the study. exclusion criteria: * hba1c over 9.0%. * patients who changed medication within 1 months before inclusion. * judged as ineligible by clinical investigators. hospitalization arm inclusion criteria: * type 2 diabetes patient who were hospitalized for congestive heart failure. * patients who have given informed consent to participation in the study. exclusion criteria: * patients on insulin therapy. * judged as ineligible by clinical investigators.
necrotizing enterocolitis in fetuses with intrauterine growth restriction

Conditions: Necrotizing Enterocolitis

Summary: necrotizing enterocolitis is the most common gastroenterological emergency in neonatology. its mortality is high, ranging from 15 to 30%. prematurity is the main risk factor for necrotizing enterocolitis, as well as the very low birth weight (\<1500 g) associated with prematurity. among the early neonatal complications of intrauterine growth restriction neonates, necrotizing enterocolitis is frequently reported in the literature. the situation of chronic hypoxia of these fetuses is at the origin of a vascular redistribution favoring the cerebral circulation to the detriment of the mesenteric vascularization, which could lead to the development of an necrotizing enterocolitis. however, data from the literature concerning this over-risk of necrotizing enterocolitis in the case of intrauterine growth restriction are discordant. the heterogeneity of the definitions used for the intrauterine growth restriction and diagnostic criteria for necrotizing enterocolitis from one study to another could explain these discrepancies. the investigator's hypothesis is that the risk of necrotizing enterocolitis is higher among newborns in intrauterine growth restriction compared to control children.


Eligibility criteria:
inclusion criteria: * all birth between 24 + 0 weeks of amenorrhea and 36 + 6 weeks of amenorrhea * with isolated intrauterine growth restriction at the maternity ward of the hospital femme-mère-enfant * from 1st of january 2011 to 31 december 2016. inclusion criteria for control group: * all birth between 24 + 0 weeks of amenorrhea and 36 + 6 weeks of amenorrhea * without isolated intrauterine growth restriction at the maternity ward of the hospital femme-mère-enfant * from 1st of january 2011 to 31 december 2016. exclusion criteria: * infants born out of the hospital and secondarily hospitalized in our department * unaccompanied pregnancies * multiple pregnancies * children with malformations or genetic abnormalities, * medical termination of pregnancy * fetal deaths in utero
development of a neonatal jaundice treatment accelerator by redirection of unused light during phototherapy

Conditions: Jaundice; Jaundice, Neonatal

Summary: this is a descriptive prospective study of safety and efficacy of the reflective pt ring device. neonates with an elevated total serum bilirubin (tsb) meeting pt criteria per their clinician during hospital admission will be eligible for enrollment after informed parental consent.

neonatal jaundice (nnj) continues to be a significant global problem affecting over 80% of neonates while severe neonatal jaundice affects at least 481,000 neonates annually. jaundice and jaundice related complications like kernicterus spectrum disorder (kds) are gaining recognition among the world's health policy leaders as an important area for further research and development. the long-term sequelae of ksd include choreoathetoid cerebral palsy, sensorineural hearing loss, and upward gaze palsy. ksd is irreversible resulting in a lifetime of physical, emotional, social and economic challenges. access to cost-effective methods of improving pediatric jaundice care along with improved circumferential (full body) illumination technologies is an affirmed objective of the aap (american academy of pediatrics). the investigators hypothesize that unused therapy light (irradiance) surrounding the neonate using an existing single-lamp bank phototherapy (pt) device is sufficient in quantity and if redirected onto the patients untreated or poorly illuminated skin surfaces, it will accelerate metabolism and excretion of bilirubin. this pt ring device redirects unused phototherapy light sideways onto the neonate body using an open-faced ring approach. the technology will illuminate previously unexposed and poorly exposed skin regions where treatable bilirubin exists. the device is superior to current pt devices in that it converts existing waste light into treatment efficacy while integrating into existing overhead lamp systems offsetting the purchase of secondary devices that are often unaffordable and create hospital complexity, cost and inefficiency issues. a further benefit of the device will be reduced ambient blue-light spillover in patient care areas, an ongoing concern for medical staff.

Eligibility criteria:
inclusion criteria: * males or female neonates greater than or equal to 35 weeks gestational age * elevated total serum bilirubin levels meeting pt criteria in the first 7 days of life exclusion criteria: * neonates, who are mechanically ventilated * neonates requiring continuous positive airway pressure * neonates with a history of apnea, bradycardia * patients with known cyanotic heart disease * patients experiencing temperature instability or desaturation episodes in 24hr prior to enrollment will be excluded. * parents/guardians or subjects who, in the opinion of the investigator, may be non-compliant with study schedules or procedures.
foods: food shoppers' social media study

Conditions: Eating Behaviour of Discretionary Foods; Cognitive Restraint of Eating; Physical Activity; Body Weight

Summary: this study aims to assess the effects of a new approach to food labelling called physical activity calorie equivalent (pace) labelling. pace food labelling provides the public with information about how many minutes (or miles/kilometres) of physical activity (e.g. walking or running) are equivalent to the calories contained in foods.


Eligibility criteria:
inclusion criteria: * ≥ 18 years old. * bmi of ≥ 18.5 kg/m2. * ≤ 3kg weight loss in previous 6 months. * access and ability to use personal twitter and/or instagram account via own smartphone, computer or tablet device. * access to the internet. * access to a set of weighing scales. exclusion criteria: * unable to read and understand english. * experienced in the last 12 months or currently undergoing any of the following conditions or illnesses: coronary heart disease (chd), hypertension, heart failure, stroke/transient ischaemic attack, atrial fibrillation, type 2 diabetes, chronic obstructive pulmonary disease (copd), painful condition, dementia and cancer. * had bariatric surgery. * pregnant, lactating or planning to become pregnant in the next 12 months. * parallel participation in another weight, dietary or physical activity intervention study.

Keywords: nutrition labelling physical activity social media
rebeccamycin analog in treating patients with advanced kidney cancer

Conditions: Kidney Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of rebeccamycin analog in treating patients who have advanced kidney cancer.

objectives: * determine the response rate of patients with advanced renal cell carcinoma when treated with rebeccamycin analogue. * assess the quantitative and qualitative toxicities associated with this drug in this patient population. outline: patients receive rebeccamycin analogue iv over 30-60 minutes daily for 5 days. treatment continues every 21 days in the absence of disease progression or unacceptable toxicity. projected accrual: a total of 23-44 patients will be accrued for this study within 9-18 months.

Eligibility criteria:
disease characteristics: * histologically or cytologically confirmed locally advanced unresectable, locally recurrent, or metastatic renal cell carcinoma not eligible for a higher priority trial * measurable disease * longest diameter at least 20 mm with conventional techniques or at least 10 mm with spiral ct scan * no nonmeasurable disease only including: * bone lesions * leptomeningeal disease * ascites * pleural/pericardial effusion * lymphangitis cutis/pulmonis * abdominal masses not confirmed and followed by imaging techniques * cystic lesions * no known brain metastases * history of brain metastases that have been resected and/or irradiated with subsequent normal brain ct scan allowed patient characteristics: age: * 18 and over performance status: * ecog 0-2 or * karnofsky 60-100% life expectancy: * greater than 12 weeks hematopoietic: * absolute neutrophil count at least 1,500/mm\^3 * platelet count at least 100,000/mm\^3 hepatic: * bilirubin no greater than 1.5 mg/dl * ast/alt no greater than 2.5 times upper limit of normal renal: * creatinine no greater than 1.5 mg/dl or * creatinine clearance at least 60 ml/min cardiovascular: * no symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia other: * not pregnant or nursing * fertile patients must use effective contraception * no other prior malignancy within the past 2 years except nonmelanoma skin cancer or carcinoma in situ of any site * no history of allergic reactions attributed to compounds of similar chemical or biologic composition to rebeccamycin analogue * no other concurrent uncontrolled illness (e.g., ongoing or active infection) * no concurrent psychiatric illness or social situation that would preclude study compliance * hiv negative prior concurrent therapy: biologic therapy: * prior biologic therapy allowed * recovered from toxic effects chemotherapy: * no prior chemotherapy endocrine therapy: * not specified radiotherapy: * see disease characteristics * at least 4 weeks since prior radiotherapy and recovered surgery: * see disease characteristics other: * no other concurrent investigational or commercial agents or therapies for renal cell cancer

Keywords: stage iii renal cell cancer stage iv renal cell cancer recurrent renal cell cancer
use and decision-making about colorectal cancer screening among hispanic men and women

Conditions: Colorectal Cancer

Summary: during this first year, the researchers have worked toward identifying factors influencing initiation of colorectal cancer screening among hispanic men and women aged 50 and older and developing an intervention plan using intervention mapping, a framework for systematic health promotion program planning, implementation, and evaluation. the researchers are also currently in the preliminary stages of developing two promotora (lay health worker)-delivered interventions: a small media intervention (video, flip chart, pamphlets) and a tailored interactive multimedia intervention, prior to the actual collection of data. thus, although 733 subjects have been approved by the committee for the protection of human subjects to be enrolled in this study in the future, no subjects have been enrolled at this time. consequently, there have been no adverse events, and since the risks associated with participating in this study are negligible, the researchers do not anticipate any adverse events in the future. no modifications have been made to the research since the last review, other than that the researchers are currently reassessing the need to conduct preliminary qualitative research as proposed in the original protocol.

during this first year, the researchers have worked toward identifying factors influencing initiation of colorectal cancer screening among hispanic men and women aged 50 and older and developing an intervention plan using intervention mapping, a framework for systematic health promotion program planning, implementation, and evaluation. the researchers are also currently in the preliminary stages of developing two promotora (lay health worker)-delivered interventions: a small media intervention (video, flip chart, pamphlets) and a tailored interactive multimedia intervention, prior to the actual collection of data. thus, although 733 subjects have been approved by the committee for the protection of human subjects to be enrolled in this study in the future, no subjects have been enrolled at this time. consequently, there have been no adverse events, and since the risks associated with participating in this study are negligible, the researchers do not anticipate any adverse events in the future. no modifications have been made to the research since the last review, other than that the researchers are currently reassessing the need to conduct preliminary qualitative research as proposed in the original protocol.

Eligibility criteria:
exclusion criteria: * personal history of colorectal cancer

Keywords: screening, community health education, decision making, computer-assisted decision making
study of oncological outcomes of d3 lymph node dissection in colon cancer

Conditions: Colonic Neoplasms Malignant

Summary: the purpose of this study is to determine wether d3 lymph node dissection gives superior oncological outcomes compared to standard d2 lymph node dissection in colon cancer

the design involves random allocation of eligible patients to d3 or d2 lymph node dissection group in 1:1 ratio. the extent of colonic resection itself is not influenced by the randomization and is predefined by the investigator prior to randomization. requirements applied to centers participating in the trial and surgeons performing procedures are described in the protocol and refer to center volume and surgeon's experience with evaluation of non-edited video-recordings of procedures. routine quality control includes requirement to photograph vessels with the clip to determine the extent of lymph node dissection performed and a thorough morphological assessment of the specimen. after surgery patients are treated according to local standards with no difference wether d2 or d3 lymph node dissection was performed. short-term and long-term outcomes are registered as per protocol. this is a superiority trial evaluating statistical superiority. with the 50% five year survival according to national registry for colon cancer, expecting 10% improvement in survival with d3 lymph node dissection, enrollment of 768 patients during 3 year accrual period followed by 5 year follow up is required for a power of 80%. the intent-to-treat principle is used for the data analysis.

Eligibility criteria:
inclusion criteria: * histologically confirmed adenocarcinoma of the colon (caecum, ascending, transverse, descending, sigmoid) * clinical stage t1-4an0-2m0-1 (distant metastases must be resectable) * indications for surgical colonic resection * ecog status 0-2 * at least 18 years of age * written informed consent exclusion criteria: * medical or psychiatric conditions that compromise the patient's ability to give informed consent or comply with the study protocol * pregnancy or breast feeding * medical contraindications for surgical treatment * synchronous or metachronous malignancy * non-resectable distant metastases * colon obstruction, perforation or bleeding complicating the tumor * indications for isolated transverse colon resection * neoadjuvant chemotherapy

Keywords: colon cancer lymph node dissection d3 lymph node dissection